bci

BCI ((E)-BCI) is an allosteric inhibitor of dual-specificity phosphatases (DUSP), with EC50 values of 13.3 μM for DUSP6 and 8.0 μM for DUSP1 in cells, and does not inhibit DUSP5.

BCI hydrochloride ((E)-BCI hydrochloride) is a selective dual-specificity phosphatase 6 (DUSP6) inhibitor that inhibits RANKL-mediated osteoclastogenesis and attenuates oophorectomy-induced bone loss.BCI hydrochloride has anti-inflammatory activity, reduces reactive oxygen species (ROS) production, and partially reverses AE-induced bone loss. BCI hydrochloride has anti-inflammatory activity and can reduce reactive oxygen species (ROS) production, partially reverse AE-induced cytotoxicity, and increase ERK activity, which can be used to study inflammatory diseases.

(E/Z)-BCI (NSC-150117), a dual-specificity phosphatase 6 (DUSP6) inhibitor with anti-inflammatory properties, reduces LPS-induced inflammatory mediators and ROS production in macrophage cells by activating the Nrf2 signaling axis and inhibiting the NF-κB pathway.

BCI-121 is a substrate-competitive SMYD3 inhibitor that inhibits the proliferation of the cancer cell.

BCI-215 causes selective cancer cell cytotoxicity in part through non-redox-mediated activation of MAPK signaling

Sabcomeline is a selective M1 receptor partial agonist.

BCI-137 is an Argonaute 2 ligand. It acts by targeting the MicroRNA binding domain.

MGS-0210 (also known as BCI-838) is an orally active prodrug of an mGluR2/3 receptor antagonist.

PROTACBcI-2/BcI-xI Degrader-1 (15) is a PROTAC degrader targeting BcI-2/BcI-xI.

BcI-2/BcI-xI ligand 1, functioning as a BcI-2/BcI-xI ligand, is utilized in the synthesis of PROTAC BcI-2/BcI-xI Degrader-1 .

DCBCI0901 is an inhibitor of phosphatidylinositide 3-kinase (PI3K), raptor-mTOR (mTOR complex 1 or mTORC1) and rictor-mTOR (mTOR complex 2 or mTORC2) with potential antineoplastic activity.

Bismuth Subcitrate Potassium is an antibiotic that acts against 12 species of Helicobacter pylori, inhibits the histamine H2 receptor, and can be used to study diarrhea and peptic ulcer disease in vulnerable patients with SARS-CoV-2 infections.

Abciximab (C7E3) is a mouse/human chimeric monoclonal antibody that is a potent glycoprotein IIb/IIIa inhibitor. Abciximab has anti-platelet aggregation and leukocyte adhesion, acting by binding to glycoproteins IIb/IIIa, vitronectin and Mac-1 receptors.

Lotilibcin (WAP-8294A2) is an antibiotic originally isolated from the Lysobacter sp.

BCIP (potassium) is a chromogenic substrate commonly utilized to assess alkaline phosphatase enzyme activity. Upon dephosphorylation by alkaline phosphatase, BCIP forms a blue precipitate.

Citronellol ((±)-β-Citronellol) is used in insect repellents and perfumes and as a mite attractant.

Tofacitinib Citrate (CP-690550 citrate) is a a potent, cell-permeable inhibitor of JAK1/2/3 (IC50s: 1/20/112 nM).

Gastrodenol (Bismuth tripotassium dicitrate) is a bismuth compound used for peptic ulcer and gastro-oesophageal reflux disease.

Ixazomib citrate (MLN9708) is a prodrug of Ixazomib (MLN-2238) and an orally bioavailable second-generation proteasome inhibitor with an IC50 of 3.4 nM, exhibiting potential antineoplastic activity.

L-Citronellol ((S)-(-)-beta-Citronellol) is a small molecule compound isolated from geranium with antifungal activity, affecting fungal membranes.L-Citronellol acts synergistically with amphotericin B against Candida yeast.

Tobramycin Sulfate (Dartobcin) is an antibacterial nanomedicine, useful in pediatric bacterial pneumonia research.

MLN2238 suppresses the chymotrypsin-like proteolytic (β5) site of the 20S proteasome(Ki50=0.93 nM, IC50=3.4 nM/). The biologically active form of MLN9708 (Ixazomib Citrate) is MLN2238 in aqueous solutions or plasma.

Zotiraciclib (also known as TG02 and SB1317) is an innovative small-molecule compound with potent inhibitory effects on CDK, JAK2, and FLT3. By inhibiting cyclin-dependent kinase 9 (CDK9) and depleting Myc, it serves as a treatment for cancers that can penetrate the blood-brain barrier. Zotiraciclib is one of the numerous CDK inhibitors under investigation; other compounds targeting CDK9, utilized for treating acute myeloid leukemia, include alvocidib and atuveciclib. Myc overexpression is a known factor in many cancers, with 80% of glioblastomas exhibiting this characteristic.

Revumenib (also known as SNDX-5613) is an effective and selective Menin-MLL inhibitor. It is primarily used for the study of MLL-rearranged (MLL-r) acute leukemias, including acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML).